| Document |
Document Title |
|
WO/2024/077445A1 |
Provided are a 5'UTR element comprising a nucleotide sequence as shown in SEQ ID NO: 11 and the use thereof in the production of L-arginine. Further provided are a functional expression element containing the 5'UTR element and a promoter...
|
|
WO/2024/080483A1 |
The present invention relates to a CRISPR-Cas-based composition for detection of Listeria monocytogenes and a Listeria monocytogenes detection method using same and, more specifically, to a composition for detection of Listeria monocytog...
|
|
WO/2024/077509A1 |
Provided in the present invention are a pharmaceutical composition for preventing and treating poxvirus infections and diseases caused thereby and the use thereof. The pharmaceutical composition comprises: (1) interferon-β and interfero...
|
|
WO/2024/078633A1 |
Provided is a gene regulation strategy enabling programmable control over eukaryotic translational initiation and use of said gene regulation strategy for various biomedical purposes including but not limited to therapeutic transgene del...
|
|
WO/2024/081375A1 |
Provided herein are plants having enhanced lignification of root exodermis and methods of generating such plants.
|
|
WO/2024/080569A1 |
The present disclosure relates to a recombinant protein of beta-galactosidase-1 (GLB1) with a truncated C-terminus; a pharmaceutical composition for the treatment, prevention or amelioration of GM1 gangliosidosis or Morquio syndrome B,...
|
|
WO/2024/079658A1 |
This disclosure provides BDNF expression constructs and vectors comprising such constructs for treating metabolic disorders, including, but not limited to, obesity. The disclosed BDNF gene therapy is more effective than existing BDNF-bas...
|
|
WO/2024/081791A2 |
Embodiments disclosed herein provide compositions for increasing CCL3 and/or CCL4 interactions with CCR5 and/or CCR1 to enhance an immune response. Applicants identified specific interactions between CD8+ T cells and inflammatory monocyt...
|
|
WO/2024/078367A1 |
A recombinant organism and a method for producing mycosporine-like amino acids. The method comprises: an organism construction step, comprising: providing an organism of which endogenous genes are knocked out, and integrating an xylose m...
|
|
WO/2024/077984A1 |
The present invention belongs to the technical field of molecular breeding in maize. Provided are a maize dwarfing-related molecular marker having semi-dominance and the use thereof. The maize dwarfing-related molecular marker is caused ...
|
|
WO/2024/078479A1 |
The present invention relates to a heterodimeric fusion protein and the use thereof. The heterodimeric fusion protein of the present invention comprises: a first heavy chain, wherein the first heavy chain comprises a first Fc region and ...
|
|
WO/2024/078288A1 |
Disclosed in the present invention are an anti-RCP antibody and a preparation method therefor. The anti-RCP antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region compr...
|
|
WO/2024/077376A1 |
Acute myeloid leukemia (AML) has not benefited from innovative immunotherapies, mainly because of the lack of actionable immune targets. Novel tumor-specific antigens (TSAs) shared by a large proportion of AML cells are described herein....
|
|
WO/2024/077428A1 |
Provided is an enzyme with D-amino acid synthesis activity. The enzyme has an amino acid sequence as shown in SEQ ID NO: 10. Compared with an original strain before mutation, the enzyme has a higher catalytic activity for D-amino acid sy...
|
|
WO/2024/078995A1 |
The present invention provides an in-vitro method for transferring one or more nucleic acids sequences comprising one or more transgenes into γδ T cells with a pseudotyped retroviral vector particle or a virus-like particle thereof, wh...
|
|
WO/2024/078621A1 |
Disclosed are a nanopore mutant protein and a use thereof. The nanopore mutant protein comprises one or more amino acids of the wild-type PHT nanopore protein as represented by SEQ ID NO: 1 being mutated into other amino acids, or knocko...
|
|
WO/2024/077351A1 |
The invention relates to oligonucleotides that inhibit Toll-Like Receptor 7 (TLR7) and/or Toll-Like Receptor 8 (TLR8), or potentiate TLR8, and uses thereof.
|
|
WO/2024/081912A1 |
Disclosed herein include methods, compositions, and kits suitable for use in signal amplification. There are provided, in some embodiments, protease-based signal amplification modules. Disclosed herein include amplifier proteins comprisi...
|
|
WO/2024/081673A2 |
The present disclosure provides, among other things, systems, engineered cell lines and methods of manufacturing recombinant viral vectors and products. Engineered cell lines comprise one, two, three, or more stably integrated genomic co...
|
|
WO/2024/079140A1 |
The present invention relates to a method for modifying a promoter to obtain a promoter variant comprising the steps of: a. providing a promoter, b. modifying the promoter - by inserting at least one nucleic acid se- quence selected from...
|
|
WO/2024/080067A1 |
The present invention provides a novel genome editing means that makes it possible to recognize a novel PAM sequence in a eukaryotic cell genome and site-specifically modify the genome. Provided is a method for site-specifically modifyin...
|
|
WO/2024/078584A1 |
Provided are a method for modifying a capsid protein coding sequence of a cap gene of an adeno-associated virus (AAV), and an AAV capsid protein coding sequence obtained via the method. Additionally provided is the use of a modified AAV ...
|
|
WO/2024/079361A1 |
The invention relates to a protein- or peptide-based capsule (PPC), preferably a VLP, loaded with a messenger RNA (mRNA). The invention further relates to an mRNA, and a pharmaceutical composition and a drug delivery system (DOS) compris...
|
|
WO/2023/240156A9 |
Provided are ionizable cationic lipids and lipid nanoparticles for the delivery of nucleic acids to cells (e.g., immune cells), and methods of making and using such lipids and targeted lipid nanoparticles.
|
|
WO/2024/081687A2 |
Provided herein are methods of treating leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation (LBSL) in a subject in need thereof, the method comprising: administering an adeno-associated virus (AAV) vector...
|
|
WO/2024/079449A1 |
The invention relates to a construct and AAV particle comprising a wildtype NDP nucleic acid sequence or a codon-optimised NDP nucleic acid sequence. The invention further relates to products and methods for the treatment of one or more ...
|
|
WO/2024/081888A1 |
Disclosed herein are methods for regulating expression of a gene located on an episomal vector in a subject in need thereof. In particular, methods include administering to the subject one or more gene editing agents that modify a region...
|
|
WO/2024/079531A2 |
The application relates to nucleic acid regulatory elements (NAREs) that are able to enhance expression of genes in the liver. The application further relates to methods employing NAREs and uses of the NAREs. Expression cassettes and vec...
|
|
WO/2024/081899A1 |
This invention relates to the finding that novel splice switching oligonucleotides can correct splicing mutations. Moreover, the invention relates to using the novel splice switching oligonucleotides to correct a 1811+1.6kb G>T (c.1679+1...
|
|
WO/2024/080306A1 |
According to one embodiment of the present invention, it is possible to efficiently produce a highly-active recombinant protein by expressing, in the form of a fusion protein with serum albumin (SA), a physiologically-active protein havi...
|
|
WO/2024/077214A1 |
The disclosure relates to nucleic acid-based vaccines for cancer and other diseases.
|
|
WO/2024/075767A1 |
The purpose of the present invention is to provide: a method for conveniently introducing a gene into a mitochondrion from the outside of a cell; and a method for introducing a nucleic acid having a relatively large size into a mitochond...
|
|
WO/2024/077110A2 |
The present disclosure provides isolated polynucleotides comprising sequences encoding uORF peptides and variants and fragments thereof. The present disclosure also provides constructs and vectors containing the polynucleotides. The pres...
|
|
WO/2024/077256A1 |
The present invention discloses methods and platforms for generating protein binding proteins with specificity for native peptide-MHC (pMHC) complexes. The pMHC binding proteins can be used in bi-specific antibodies or for generating CAR...
|
|
WO/2024/076940A1 |
Nucleic acids are described that encode for triggering receptor expressed on myeloid cells 2 (TREM2) and that can be used in expression constructs, vectors and gene therapies. Also described are methods of using the same for the treatmen...
|
|
WO/2024/074670A1 |
The invention relates to the fields of medicine and immunology. In particular, it relates to novel antisense oligonucleotides that may be used in the treatment, prevention and/or delay of an USH2A-related disease or condition.
|
|
WO/2024/075112A1 |
Provided herein are recombinant AAT proteins having high fucosylation levels and enhanced immunomodulatory biological activity as compared to a plasma derived AAT. Further provided are compositions including the same and methods for prep...
|
|
WO/2023/133593A9 |
Disclosed herein are recombinant AAV variant (e.g., variant serotype 5 (AAV5)) capsid proteins and variant capsid protein-containing viral particles with enhanced ability to transduce adult stem cells and neurons. Viral particles contain...
|
|
WO/2024/074584A1 |
The present invention relates to stabilized pre-fusion human parainfluenza virus 3 (HPIV3) F protein, and fragments thereof. The invention also relates to nucleic acid molecules encoding such proteins and fragments, and to the use of the...
|
|
WO/2024/075851A1 |
The purpose of the present invention is to provide a novel nucleic acid construct that induces antibody production. The present invention provides a nucleic acid construct that induces antibody production against a target protein, the nu...
|
|
WO/2024/074105A1 |
The present invention belongs to the field of biopharmaceuticals. Provided in the present invention are keratin YK93-4, a nucleic acid molecule encoding same, an expression vector containing the nucleic acid molecule, a host cell contain...
|
|
WO/2024/077170A1 |
Provided are antibodies that specifically bind to human urokinase-type plasminogen activator receptor (uPAR). In some instances, the antibodies are cross-reactive one or more non-human animal uPAR polypeptides, such as a non-human primat...
|
|
WO/2024/075597A1 |
Provided is a method for manufacturing a copolymer polyhydroxyalkanoic acid mixture by culturing a microorganism. The mixture contains: a fraction (I) which includes a copolymer polyhydroxyalkanoic acid having a 3-hydroxybutyric acid str...
|
|
WO/2024/075559A1 |
This nucleic acid extraction method comprises: producing an antibody-copolymer conjugate by preparing, in the absence of a protease, a mixture including at least one sample selected from the group consisting of cells, extracellular vesic...
|
|
WO/2024/075838A1 |
A pulmonary fibrosis model that includes a co-culture system containing alveolar organoids and pulmonary fibroblasts that express a reporter gene when converted into myofibroblasts, wherein, when the alveolar organoids are injured, the p...
|
|
WO/2024/076190A1 |
The present invention provides a mutant of adeno-associated virus serotype 1 (AAV1) capsid protein, a nucleic acid encoding the mutant of AAV1 capsid protein, a recombinant AAV1 vector carrying the nucleic acid encoding the mutant of AAV...
|
|
WO/2024/074706A1 |
Disclosed herein are designed ankyrin repeat domain specifically binding to fibroblast activation protein (FAP). Such designed ankyrin repeat domains can be used in recombinant adapter molecules that are displayed on adenoviruses. Adenov...
|
|
WO/2024/077089A2 |
The disclosure relates generally to methods of producing recombinant viral vectors with reduced immunogenicity.
|
|
WO/2024/075012A1 |
The disclosure provides improved host cells for producing recombinant adeno-associated virus (AAV) vectors, methods of producing AAV vectors using such improved host cells, and AAV vectors produced thereby.
|
|
WO/2024/075819A1 |
The purpose of the present invention is to provide, in virus vector production, a method for efficiently producing a virus vector having a high infectious titer. Provided is a virus vector production method including a step for culturing...
|
